• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CXS
Click for more information
0.00% 70.0¢

CHEMGENEX PHARMACEUTICALS LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CXSAppendix 3B28/10/10
CXSNotice of Annual General Meeting/Proxy Form22/10/10
CXSAnnual Report to shareholders22/10/10
CXSChange of Director's Interest Notice22/10/10
CXSChange of Director's Interest Notice22/10/10
CXSBecoming a substantial holder22/10/10
CXSConvertible Note Issued to Cephalon, IncPRICE SENSITIVE22/10/10
CXSAppendix 3B15/10/10
CXSResponse to an ASX Price QueryPRICE SENSITIVE05/10/10
CXSChemGenex Completes pre-NDA Meeting with U.S. FDAPRICE SENSITIVE05/10/10
CXSPresentation at International Investment Conference13/09/10
CXSAppendix 3B06/09/10
CXSPreliminary Final ReportPRICE SENSITIVE27/08/10
CXSAppendix 3B09/08/10
CXSAppendix 3B02/08/10
CXSFDA agrees on potential regulatory pathway for OMAPROPRICE SENSITIVE14/07/10
CXSChange of Director's Interest Notice28/06/10
CXSAppendix 3B28/06/10
CXSChange in substantial holding17/06/10
CXSAppendix 3B15/06/10
CXSAnnounces updated OMAPRO safety data at ASCO07/06/10
CXSAppendix 3B12/05/10
CXSInvestor Update04/05/10
CXSComplete Response Letter from FDA ReceivedPRICE SENSITIVE12/04/10
CXSChange of Director's Interest Notice29/03/10
CXSAppendix 3B29/03/10
CXSAppendix 3B29/03/10
CXSChange in substantial holding26/03/10
CXSChange in substantial holding25/03/10
CXSODAC seeks validated diganostic before approval of OMAPROPRICE SENSITIVE23/03/10
CXSAppendix 3B18/03/10
CXSChange of Director's Interest Notice16/03/10
CXSAppendix 3B16/03/10
CXSAppendix 3B15/03/10
CXSAppendix 3B15/03/10
CXSAppendix 3B04/03/10
CXSODAC Meeting Rescheduled to 22 March 201002/03/10
CXSHalf Yearly Report and AccountsPRICE SENSITIVE25/02/10
CXSChange in substantial holding22/02/10
CXSChange of Director's Interest Notice11/02/10
CXSCXSO Option Expiry09/02/10
CXSODAC Postponed Due to Extreme Weather in Washington DCPRICE SENSITIVE09/02/10
CXSAppendix 3B29/01/10
CXSAppendix 3B20/01/10
CXSAppendix 3B06/01/10
CXSChange in substantial holding31/12/09
CXSDetails of Share Registry address17/12/09
CXSAppendix 3B17/12/09
CXSOmapro ODAC meeting confirmed for 10 February 2010PRICE SENSITIVE17/12/09
CXSInvestor Briefing - Teleconference/Webcast14/12/09
CXSOmacetaxine European rights licensed to HospiraPRICE SENSITIVE14/12/09
CXSUpdated omacetaxine data from multiTKI failure studyPRICE SENSITIVE09/12/09
CXSOmapro Data Highlighted at ASH Press ConferencePRICE SENSITIVE07/12/09
CXSChange of Director's Interest Notice03/12/09
CXSAppendix 3B01/12/09
CXSPresentation of Data at Annual ASH Meeting01/12/09
CXSAppendix 3B30/11/09
CXSResults of Meeting30/11/09
CXSChairman's Address to Shareholders30/11/09
CXSCEO's Presentation AGM 200930/11/09
CXSEMEA validates ChemGenex's MAA for omacetaxinePRICE SENSITIVE27/11/09
CXSUS FDA accepts Omapro NDA - grants priority reviewPRICE SENSITIVE10/11/09
CXSAppendix 3B02/11/09
CXSAnnual Report to shareholders28/10/09
CXSNotice of Annual General Meeting/Proxy Form28/10/09
CXSCEO Receives AusBiotech Award28/10/09
CXSCorporate presentation September 200910/09/09
CXSPresentation at International Investment Conference09/09/09
CXSSubmits New Drug Application for Omacetaxine to FDA09/09/09
CXSPreliminary Final ReportPRICE SENSITIVE27/08/09
CXSDetails of Share Registry address19/08/09
CXSAppendix 3B10/08/09
CXSDirector Appointment/Resignation21/07/09
CXSAppointment of Chief Commercial Officer20/07/09
CXSAppendix 3B07/07/09
CXSChemGenex to de-list from NASDAQ and restructure Board29/06/09
CXSAppendix 3B25/06/09
CXSResponse to an ASX Query - Director's Interest Notice24/06/09
CXSChange in substantial holding17/06/09
CXSChange of Director's Interest Notice12/06/09
CXSChange of Director's Interest Notice12/06/09
CXSChange of Director's Interest Notice12/06/09
CXSInvestor Update11/06/09
CXSInvestor briefing teleconference/webcast10/06/09
CXSOmacetaxine Kills Leukemic Stem Cells in Human CML ModelsPRICE SENSITIVE09/06/09
CXSOmacetaxine Shows Activity in Refractory CMLPRICE SENSITIVE09/06/09
CXSOmacetaxine Clinical Data Presented at ASCOPRICE SENSITIVE02/06/09
CXSChange in substantial holding01/06/09
CXSDetails of Rights Issue Scale-Back29/05/09
CXSRights Issue Fully Subscribed, Further $1 Million PlacementPRICE SENSITIVE27/05/09
CXSs708A(5)(e) Disclosure Notice - Share issuance27/05/09
CXSAppendix 3B27/05/09
CXSOmacetaxine to be Showcased at EHA21/05/09
CXSRights Issue Entitlement Reminder15/05/09
CXSOmacetaxine Oral Presentation at ASCO15/05/09
CXSChange of Director's Interest Notice14/05/09
CXSInvestor Roadshow presentation11/05/09
CXSRights Issue Information sent to Shareholders04/05/09
CXSChange of Director's Interest Notice04/05/09
CXSCFO and Company Secretary Transition04/05/09
CXSAppendix 3B
28/10/10
CXSNotice of Annual General Meeting/Proxy Form
22/10/10
CXSAnnual Report to shareholders
22/10/10
CXSChange of Director's Interest Notice
22/10/10
CXSChange of Director's Interest Notice
22/10/10
CXSBecoming a substantial holder
22/10/10
CXSConvertible Note Issued to Cephalon, Inc
22/10/10PRICE SENSITIVE
CXSAppendix 3B
15/10/10
CXSResponse to an ASX Price Query
05/10/10PRICE SENSITIVE
CXSChemGenex Completes pre-NDA Meeting with U.S. FDA
05/10/10PRICE SENSITIVE
CXSPresentation at International Investment Conference
13/09/10
CXSAppendix 3B
06/09/10
CXSPreliminary Final Report
27/08/10PRICE SENSITIVE
CXSAppendix 3B
09/08/10
CXSAppendix 3B
02/08/10
CXSFDA agrees on potential regulatory pathway for OMAPRO
14/07/10PRICE SENSITIVE
CXSChange of Director's Interest Notice
28/06/10
CXSAppendix 3B
28/06/10
CXSChange in substantial holding
17/06/10
CXSAppendix 3B
15/06/10
CXSAnnounces updated OMAPRO safety data at ASCO
07/06/10
CXSAppendix 3B
12/05/10
CXSInvestor Update
04/05/10
CXSComplete Response Letter from FDA Received
12/04/10PRICE SENSITIVE
CXSChange of Director's Interest Notice
29/03/10
CXSAppendix 3B
29/03/10
CXSAppendix 3B
29/03/10
CXSChange in substantial holding
26/03/10
CXSChange in substantial holding
25/03/10
CXSODAC seeks validated diganostic before approval of OMAPRO
23/03/10PRICE SENSITIVE
CXSAppendix 3B
18/03/10
CXSChange of Director's Interest Notice
16/03/10
CXSAppendix 3B
16/03/10
CXSAppendix 3B
15/03/10
CXSAppendix 3B
15/03/10
CXSAppendix 3B
04/03/10
CXSODAC Meeting Rescheduled to 22 March 2010
02/03/10
CXSHalf Yearly Report and Accounts
25/02/10PRICE SENSITIVE
CXSChange in substantial holding
22/02/10
CXSChange of Director's Interest Notice
11/02/10
CXSCXSO Option Expiry
09/02/10
CXSODAC Postponed Due to Extreme Weather in Washington DC
09/02/10PRICE SENSITIVE
CXSAppendix 3B
29/01/10
CXSAppendix 3B
20/01/10
CXSAppendix 3B
06/01/10
CXSChange in substantial holding
31/12/09
CXSDetails of Share Registry address
17/12/09
CXSAppendix 3B
17/12/09
CXSOmapro ODAC meeting confirmed for 10 February 2010
17/12/09PRICE SENSITIVE
CXSInvestor Briefing - Teleconference/Webcast
14/12/09
CXSOmacetaxine European rights licensed to Hospira
14/12/09PRICE SENSITIVE
CXSUpdated omacetaxine data from multiTKI failure study
09/12/09PRICE SENSITIVE
CXSOmapro Data Highlighted at ASH Press Conference
07/12/09PRICE SENSITIVE
CXSChange of Director's Interest Notice
03/12/09
CXSAppendix 3B
01/12/09
CXSPresentation of Data at Annual ASH Meeting
01/12/09
CXSAppendix 3B
30/11/09
CXSResults of Meeting
30/11/09
CXSChairman's Address to Shareholders
30/11/09
CXSCEO's Presentation AGM 2009
30/11/09
CXSEMEA validates ChemGenex's MAA for omacetaxine
27/11/09PRICE SENSITIVE
CXSUS FDA accepts Omapro NDA - grants priority review
10/11/09PRICE SENSITIVE
CXSAppendix 3B
02/11/09
CXSAnnual Report to shareholders
28/10/09
CXSNotice of Annual General Meeting/Proxy Form
28/10/09
CXSCEO Receives AusBiotech Award
28/10/09
CXSCorporate presentation September 2009
10/09/09
CXSPresentation at International Investment Conference
09/09/09
CXSSubmits New Drug Application for Omacetaxine to FDA
09/09/09
CXSPreliminary Final Report
27/08/09PRICE SENSITIVE
CXSDetails of Share Registry address
19/08/09
CXSAppendix 3B
10/08/09
CXSDirector Appointment/Resignation
21/07/09
CXSAppointment of Chief Commercial Officer
20/07/09
CXSAppendix 3B
07/07/09
CXSChemGenex to de-list from NASDAQ and restructure Board
29/06/09
CXSAppendix 3B
25/06/09
CXSResponse to an ASX Query - Director's Interest Notice
24/06/09
CXSChange in substantial holding
17/06/09
CXSChange of Director's Interest Notice
12/06/09
CXSChange of Director's Interest Notice
12/06/09
CXSChange of Director's Interest Notice
12/06/09
CXSInvestor Update
11/06/09
CXSInvestor briefing teleconference/webcast
10/06/09
CXSOmacetaxine Kills Leukemic Stem Cells in Human CML Models
09/06/09PRICE SENSITIVE
CXSOmacetaxine Shows Activity in Refractory CML
09/06/09PRICE SENSITIVE
CXSOmacetaxine Clinical Data Presented at ASCO
02/06/09PRICE SENSITIVE
CXSChange in substantial holding
01/06/09
CXSDetails of Rights Issue Scale-Back
29/05/09
CXSRights Issue Fully Subscribed, Further $1 Million Placement
27/05/09PRICE SENSITIVE
CXSs708A(5)(e) Disclosure Notice - Share issuance
27/05/09
CXSAppendix 3B
27/05/09
CXSOmacetaxine to be Showcased at EHA
21/05/09
CXSRights Issue Entitlement Reminder
15/05/09
CXSOmacetaxine Oral Presentation at ASCO
15/05/09
CXSChange of Director's Interest Notice
14/05/09
CXSInvestor Roadshow presentation
11/05/09
CXSRights Issue Information sent to Shareholders
04/05/09
CXSChange of Director's Interest Notice
04/05/09
CXSCFO and Company Secretary Transition
04/05/09
refresh Created with Sketch. REFRESH
 

Top Stories

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
Cyclone signs MOU with Vale for development of Iron Bear play Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
HotCopper Highlights: Your most watched stocks for Week 46, 2024 What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.